| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
CHD1Li 6.11 targets CHD1L (chromodomain helicase DNA binding protein 1 like), an oncogenic protein involved in chromatin remodeling. CHD1L is a target in prostate cancer research, where CHD1 loss or dysregulation plays a critical role in tumorigenesis and therapy resistance. Inhibition of CHD1L disrupts chromatin dynamics and epigenetic regulation.
|
|---|---|
| ln Vitro |
In vitro, CHD1Li 6.11 is a potent inhibitor of oncogenic CHD1L with an IC₅₀ of 3.3 μM for cat-CHD1L recombinant protein. It is an orally bioavailable antitumor agent. It is used to study epigenetic regulation, chromatin dynamics, and potential vulnerabilities in cancers dependent on chromatin remodeling pathways.
|
| ln Vivo |
In vivo, CHD1Li 6.11 significantly reduces tumor volume of CRC xenografts generated from isolated quasi-mesenchymal cells (M phenotype) that possess enhanced tumorigenic properties. It is an orally bioavailable anticancer agent. It has potential for prostate cancer research.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for CHD1Li 6.11 involves measuring the activity of cat-CHD1L recombinant protein in the presence of the compound. The IC₅₀ of 3.3 μM is determined by quantifying the reduction in CHD1L enzymatic activity.
|
| Cell Assay |
In vitro cell-based assays for CHD1Li 6.11 involve treating cancer cells with the compound and assessing cell viability, proliferation, and chromatin remodeling. The compound's effects on gene expression and epigenetic regulation are evaluated.
|
| Animal Protocol |
In vivo animal studies for CHD1Li 6.11 involve xenograft mouse models of colorectal cancer (CRC). Tumor-bearing mice are treated orally with the compound, and tumor growth inhibition is monitored.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of CHD1Li 6.11 are not extensively detailed in the available literature. The compound is orally bioavailable.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for CHD1Li 6.11 are available in the provided literature. The compound is for research use only. Standard laboratory safety precautions should be followed when handling.
|
| References | |
| Additional Infomation |
CHD1Li 6.11 is a potent CHD1L inhibitor with an IC₅₀ of 3.3 μM. It is an orally bioavailable antitumor agent. It reduces tumor volume in CRC xenografts. Its CAS number is 2716890-91-2.
|
| Molecular Formula |
C21H22BRN5OS
|
|---|---|
| Molecular Weight |
472.40
|
| Exact Mass |
471.073
|
| CAS # |
2716890-91-2
|
| PubChem CID |
156868176
|
| Appearance |
Off-white to gray to be determined
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
541
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=NC(=N1)N2CCCC2)NC3=CC=C(C=C3)NC(=O)CC4=CC(=CS4)Br
|
| InChi Key |
ACDZBXZERLBYOW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22BrN5OS/c1-14-10-19(26-21(23-14)27-8-2-3-9-27)24-16-4-6-17(7-5-16)25-20(28)12-18-11-15(22)13-29-18/h4-7,10-11,13H,2-3,8-9,12H2,1H3,(H,25,28)(H,23,24,26)
|
| Chemical Name |
2-(4-bromothiophen-2-yl)-N-[4-[(6-methyl-2-pyrrolidin-1-ylpyrimidin-4-yl)amino]phenyl]acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~211.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1169 mL | 10.5843 mL | 21.1685 mL | |
| 5 mM | 0.4234 mL | 2.1169 mL | 4.2337 mL | |
| 10 mM | 0.2117 mL | 1.0584 mL | 2.1169 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
